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Abstract
Background: Patients	with	a	history	of	anaphylaxis	are	at	risk	of	future	anaphylactic	
reactions.	Thus,	secondary	prevention	measures	are	recommended	for	these	patients	
to	prevent	or	attenuate	the	next	reaction.
Methods: Data	from	the	Anaphylaxis	Registry	were	analyzed	to	identify	secondary	
prevention	measures	offered	to	patients	who	experienced	anaphylaxis.	Our	analysis	
included	7788	cases	from	10	European	countries	and	Brazil.
Results: The	 secondary	prevention	measures	offered	varied	across	 the	elicitors.	A	
remarkable	discrepancy	was	observed	between	prevention	measures	offered	in	spe-
cialized	allergy	centers	(84%	of	patients	were	prescribed	adrenaline	autoinjectors	fol-
lowing	EAACI	guidelines)	and	outside	the	centers:	Here,	EAACI	guideline	adherence	
was	 only	 37%.	 In	 the	multivariate	 analysis,	 the	 elicitor	 of	 the	 reaction,	 age	 of	 the	
patient,	mastocytosis	as	comorbidity,	severity	of	the	reaction,	and	reimbursement/
availability	of	the	autoinjector	influence	physician's	decision	to	prescribe	one.
Conclusions: Based	on	the	low	implementation	of	guidelines	concerning	secondary	
prevention	measures	outside	of	specialized	allergy	centers,	our	findings	highlight	the	
importance	of	these	specialized	centers	and	the	requirement	of	better	education	for	
primary	healthcare	and	emergency	physicians.
K E Y W O R D S
adrenaline	autoinjector,	anaphylactic	reaction,	anaphylaxis,	epinephrine	autoinjector,	
secondary	prevention
1  | INTRODUC TION
Anaphylaxis	is	a	rapid,	potentially	life-threatening	event.	Because	of	
its	sudden	occurrence,	immediate	professional	management	cannot	
be	realized	in	most	cases.	Therefore,	preventive	measures	are	par-
ticularly	 important.	Patients	with	a	history	of	anaphylaxis	have	an	
increased	risk	of	severe	reactions	in	the	future.1	Thus,	in	this	group	
individual	secondary	prevention	measures	are	particularly	indicated.	
The	 identification,	 consequent	 avoidance	 of	 triggers,	 and	 specific	
immunotherapy	 (SIT)	 may	 decrease	 the	 probability	 of	 repeated	
anaphylactic	 reactions.2,3	Emergency	medication	and	management	
training	may	diminish	the	severity	of	the	reaction	and	prevent	fatal	
outcome.4-6	Providing	detailed	information	regarding	the	cause,	na-
ture,	 and	countermeasures	decreases	 insecurity	 and	 increases	 the	
patients’	quality	of	life.7	Therefore,	different	international	guidelines	
emphasize	the	importance	of	secondary	prevention	measures.8,9
In	this	study,	we	analyzed	the	data	acquired	from	the	Anaphylaxis	
Registry	regarding	the	range	of	secondary	prevention	measures	of-
fered	to	patients	in	specialized	allergy	centers	and	by	primary	care	
providers.	The	availability	of	an	adrenaline	autoinjector	is	one	of	the	
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most	 important	preventive	measures	 to	 reduce	the	risk	 for	severe	
outcome;	therefore,	we	focused	on	whether	the	European	Academy	
of	Allergy	and	Clinical	Immunology	(EAACI)	standards8	for	adrena-
line	autoinjector	prescription	are	followed.
2  | PATIENTS AND METHODS
2.1 | Database
The	Anaphylaxis	Registry	 is	 a	 real-life	database	 that	 collects	data	 re-
garding	 moderate	 and	 severe	 anaphylactic	 reactions.	 The	 registry	
was	described	elsewhere.10-12	One	hundred	and	 thirty-seven	special-
ized	 tertiary	allergy	centers	 from	eleven	countries	 (Germany,	Austria,	
Switzerland,	Poland,	Italy,	Spain,	Ireland,	Greece,	France,	Bulgaria,	and	
Brazil)	 contribute	 currently	 to	 the	 registry.	 Pseudonymized	 data	 of	
patients	with	anaphylaxis	 in	the	previous	year	are	 locally	captured	by	
trained	health	professionals	through	a	web	interface.	Elicitor,	symptoms,	
course,	and	treatment	of	the	reaction,	along	with	diagnostic	procedures	
and	preventive	measures,	 are	 the	 focus	of	 the	 registry.	Furthermore,	
patients’	demographic	and	medical	data	are	collected.	The	registry	was	
established	in	2007	(initially	in	German-speaking	countries	and	in	other	
countries	since	2011),	and	the	questionnaire	evolved	over	time,	includ-
ing	additional	topics	(current	version	7.0).	The	project	was	approved	by	
the	ethics	committee	at	Charité—University	Medicine	Berlin,	Germany,	
and	accredited	by	the	local	ethic	committees	in	all	participating	centers.
2.2 | Patients
We	 included	cases	 reported	between	June	2011	and	March	2018	
fulfilling	 the	modified	 National	 Institute	 of	 Allergy	 and	 Infectious	
Diseases/Food	Allergy	and	Anaphylaxis	Network	(NIAID/FAAN)	cri-
teria.13	Cases	reported	prior	to	this	time	period	were	excluded,	be-
cause	the	previous	questionnaire	versions	did	not	contain	all	items	
required	for	this	analysis.
The	scope	of	 the	 registry	 is	moderate	and	severe	anaphylactic	
reactions;	however,	it	contains	a	small	proportion	of	cases	with	mild	
anaphylactic	 symptoms,	 which	 were	 excluded	 from	 the	 analysis	
(defined	 as	 skin/mucosa	 and/or	 gastrointestinal	 symptoms	 only).	
Reactions	with	skin/mucosal	and	severe	gastrointestinal	symptoms	
(vomiting/incontinence)	caused	by	a	parenteral	elicitor	were	defined	
as	moderate	reactions	and	remained	in	the	dataset.
The	dataset	contained	7788	cases	fulfilling	the	inclusion	criteria	
(Figure	S1,	Table	S1).
2.3 | Variables
The	secondary	prevention	measures	following	the	anaphylactic	re-
action	were	asked	in	the	questionnaire	in	a	standardized	form:
1. What prophylactic measures have been instigated following the 
episode?	 The	 answers’	 options	 (multiple	 selections	 possible)	
were	 as	 follows:	 “Counseling	 about	 avoidance	 of	 the	 trigger,”	
“Prescription	 of	 emergency	 drugs,”	 “Training	 in	 emergency	
management	plan,	 including	drug	training,”	“SIT,”	and	“Others”	
(with	 an	 option	 to	 describe	 a	 measure	 in	 a	 free	 text	 form).	
For	 each	 measure,	 the	 time	 point	 of	 the	 introduction	 was	
asked	as	follows	(multiple	selections	possible):	“Already	in	place	
prior	 to	 reaction,”	 “At	 the	 emergency	 department/	 primary	
care	 prior	 to	 discharge,”	 “In	 primary	 care	 during	 a	 follow-up	
visit,”	 and	 “In	 specialist	 center	 during	 a	 follow-up	 visit.”
G R A P H I C A L  A B S T R A C T
Data	from	the	Anaphylaxis	Registry	were	analyzed	to	identify	secondary	prevention	measures	offered	to	patients	who	experienced	
anaphylaxis.	In	specialized	allergy	centers	84%	of	patients	were	prescribed	adrenaline	autoinjectors	following	EAACI	guidelines	and	only	
37%	outside	the	centers.	The	secondary	prevention	measures	offered	to	the	anaphylaxis	patients	varied	with	the	elicitor,	and	to	some	extent	
with	other	factors	such	as	patients’	age,	comorbidities,	and	reaction	severity.
Abbreviation:	AAI,	adrenaline	autoinjector
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2. What kind of emergency drugs were prescribed following the recov-
ery of the reaction?	Here,	the	multiple	selections	of	the	following	
medication	were	 offered:	 “Adrenaline	 autoinjector,”	 “Adrenaline	
inhaler,”	 “Antihistamines,”	 “β2-mimetics,”	 “Corticosteroids,”	 and	
“Other”	(free	text	possible).	The	time	point	of	the	prescription	was	
asked	as	described	for	the	question	mentioned	above.
3.	 Beginning	 with	 version	 7.0	 of	 the	 questionnaire	 (since	 March	
2017;	 597	 cases	 in	 our	 dataset	were	 reported	 during	 this	 time	
period)	 the	 following	 additional	 information	 was	 asked:	Which 
adrenaline autoinjector was prescribed? How many adrenaline auto-
injectors were prescribed? Which dosage of one adrenaline autoinjec-
tor was prescribed?
2.4 | Statistical analysis
The	data	were	analyzed	with	STATA®	15.0	statistical	software	(Stata	
Corp.).	 To	 determine	 predictors	 influencing	 the	 probability	 of	 ob-
taining	an	autoinjector	prescription,	logistic	regression	analysis	with	
robust	standard	errors	(with	study	centers	as	clustering	variable)	was	
performed.	Results	are	presented	as	odds	ratio	(OR)	with	95%	confi-
dence	intervals	and	P-values.
3  | RESULTS
3.1 | Secondary prevention measures vary across 
elicitors
Almost	all	patients	with	venom	allergy	received	emergency	medica-
tion	prescription	(99%)	and	emergency	management	training	(98%)	
at	some	point	after	the	reaction	 (Figure	1A;	absolute	numbers	are	
described	 in	 the	 figure	 legends).	 In	77%	of	 the	cases,	 SIT	was	 ini-
tiated.	Most	patients	 in	 this	group	were	prescribed	adrenaline	au-
toinjector	 (95%),	 antihistamines	 (97%),	 and	 corticosteroids	 (95%;	
Figure	1B).
Among	 patients	 with	 food	 allergy,	 trigger	 avoidance	 counsel-
ing	was	 the	most	 frequent	preventive	measure	 (98%),	 followed	by	
F I G U R E  1  Proportion	of	venom	(Panel	A:	n	=	2861;	B:	n	=	2800	C:	n	=	2607;	D:	n	=	2546),	food	(Panel	A:	n	=	2676;	B:	n	=	2637	C:	
n	=	1926;	D:	n	=	1894),	or	drug	(Panel	A:	n	=	1388;	B:	n	=	1371;	C:	n	=	1191;	D:	n	=	1187)	allergic	patients	who	were	offered	different	
secondary	measures	(A	and	C)	and	prescribed	different	emergency	medication	(B	and	D)	at	any	time	(A	and	B)	or	before	visiting	the	
specialized	allergy	center	(C	and	D)
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emergency	 drug	 prescription	 (95%)	 and	 emergency	 management	
training	 (95%;	 Figure	 1A).	Moreover,	 SIT	 was	 initiated	 in	 2.5%	 of	
these	 patients.	 Special	 extensive	 training	 programs	 and	 individual	
nutritional	counseling	were	offered	in	a	few	cases.	Patients	with	food	
allergy	 were	 less	 likely	 to	 receive	 an	 adrenaline	 autoinjector	 pre-
scription	than	those	with	venom	allergy	(85%	vs	95%).	Furthermore,	
the	 prescription	 rates	 of	 antihistamines	 (93%)	 and	 corticosteroids	
(85%)	were	slightly	lower	(Figure	1B).
Education	regarding	trigger	avoidance	was	the	most	frequent	
preventive	measure	offered	to	patients	with	drug	allergy	 (96%).	
Interestingly,	 despite	 that	 in	 case	 of	 drug	 allergy	 the	 identi-
fied	 allergen	 can	 be	 avoided	without	 a	 great	 risk	 of	 accidental	
intake,	 40%	 of	 these	 patients	 received	 emergency	 medication	
prescribed,	 particularly	 antihistamines	 and/or	 corticosteroids;	
however,	 23%	were	 also	 prescribed	 an	 adrenaline	 autoinjector	
(Figure	1A	and	B).
“Other”	secondary	prevention	measures	were	offered	to	14%	of	
the	patients	with	drug	allergy:	Testing	and	provocation	 to	provide	
alternative	safe	medication	were	the	most	common	answers	appear-
ing	in	this	category.
To	 investigate	 which	 factors	 have	 an	 influence	 on	 the	 sec-
ondary	prevention	measures	offered,	we	performed	the	analysis	
(separate	 for	 venom	 and	 food	 allergy)	 differentiating	 among	 se-
verity	grades	of	the	reaction	according	to	the	Ring	and	Messmer	
scale,14	age	groups	and	gross	domestic	product	(GDP)15	per	capita	
of	the	country	where	the	center	is	located	(low	<	15	000	$:	Brazil,	
Bulgaria,	and	Poland	n	=	242;	middle	>	15	000	$	and	<	40	000	$:	
Greece,	 Italy,	Spain,	and	France;	n	=	1216;	and	high	>	40	000	$:	
Austria,	 Germany,	 Ireland,	 and	 Switzerland	 n	 =	 4079).	 Here,	 we	
observed	that	babies	 (n	=	61)	and	the	elderly	 (>80	years,	n	=	29)	
received	less	emergency	medication,	and	particularly	fewer	auto-
injectors	prescribed	 (approximately	70%	of	 the	patients	 in	 these	
age	 groups	 received	 an	 adrenaline	 autoinjector	 prescribed	 com-
pared	with	approximately	90%	of	those	in	other	age	groups;	data	
not	shown).	Severity	of	the	reaction	had	a	slight	influence	on	the	
prescription	pattern	(data	not	shown).	As	suspected,	patients	from	
 
A) At all (after or during the visits 
in a specialized allergy center)
B) Before visit in a special‐
ized allergy center
Number of observations n = 3608 n = 4410
 Odds ratio [95%‐CI] P‐value
Odds ratio 
[95%‐CI] P‐value
Male	sex 1.13	[0.92-1.39] .233 0.94	[0.78-1.15] .593
Age	(in	years) 0.98	[0.98-0.99] <.001 0.98	[0.98-0.99] <.001
Elicitor	(vs	venom)
Food 0.36	[0.2-0.66] .001 0.28	[0.18-0.43] <.001
Others	(including	latex,	
exercise,	and	unknown	
causes	of	anaphylaxis)
0.18	[0.1-0.34] <.001 0.28	[0.18-0.43] <.001
Comorbidities
Cardiovascular	
comorbidities
1.38	[0.88—2.17] .159 1.12	[0.97-1.3] .130
Asthma 1.25	[0.92-1.7] .153 1.22	[0.99-1.5] .068
Mastocytosis 3.03	[1.26-7.28] .036 1.53	[0.99-2.36] .053
Severity	grade	III	or	IV	(vs	
grade	IIb)
1.54	[1.27-1.87] <.001 1.36	[1.19-1.55] <.001
Access	to	autoinjector	in	the	country	of	residencec	(vs	European	countries	with	reimbursement)
European	without	
reimbursement
0.53	[0.31-0.91] .02 0.44	[0.148-1.3] .135
Brazil	as	country	of	
residence
0.11	[0.08-0.16] <.001 Omittedd  
Year	of	reaction 1.06	[0.97-1.16] .176 1.1	[1.01-1.19] .026
Model	constant 3.96e-51	
[7.4e-126-	2.11e-24]
.186 4.36e-83	[1.5e-
155-1.29e-10]
.026
aOnly	patients	with	absolute	indication	for	an	adrenaline	autoinjector	according	to	EAACI	guide-
lines	were	included.	
bReactions	grade	I	was	excluded	from	the	analysis	during	database	adjustment	(Figure	S1).	
cWe	assumed	that	patients	are	residents	of	the	country	where	their	specialized	center	is	localized.	
dAs	there	were	no	cases	from	Brazil	in	which	adrenaline	autoinjector	was	prescribed	before	visit	in	
the	specialized	center,	this	variable	was	omitted	in	this	model.	
TA B L E  1  Predictors	for	patientsa	to	
get	an	adrenaline	autoinjector	prescription	
(results	of	two	separate	logistic	regression	
models)
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countries	with	lower	gross	domestic	product	were	prescribed	less	
emergency	medication	(5%-24%	less	than	in	the	countries	with	a	
high	gross	domestic	product;	data	not	shown).
3.2 | The majority of patients with anaphylaxis 
were offered adequate prophylaxis measures for the 
first time in a specialized center
As	these	data	show	the	great	majority	of	patients	were	offered	ad-
equate	secondary	prevention	measures	at	some	point,	we	aimed	to	
further	examine	whether	these	measures	were	introduced	during	a	
visit	to	a	specialized	allergy	center	or	previously	in	a	primary	care	set-
ting/emergency	department.	For	this	analysis,	the	patients	who	di-
rectly	received	emergency	treatment	in	a	specialized	center	or	were	
visited	by	a	center	member	during	hospitalization	immediately	after	
the	 reaction	had	 to	be	excluded	 to	avoid	bias.	Thus,	only	patients	
who	presented	in	the	center	for	the	first	time	at	least	2	days	after	
the	reaction	were	included	in	this	part	of	the	analysis.	Therefore,	the	
total	number	of	cases	decreased	from	n	=	7788	to	n	=	6354.
The	most	common	secondary	prevention	measure	offered	to	the	
patients	before	consultations	in	a	specialized	center	was	emergency	
drug	prescription	 (58%	and	38%	of	patients	with	venom	and	 food	
allergies,	respectively;	Figure	1C).	In	the	venom	group,	the	percent-
age	of	patients	who	received	antihistamines	 (51%),	corticosteroids	
(50%),	and	an	adrenaline	autoinjector	 (48%)	prescribed	by	 the	pri-
mary	care/emergency	physicians	was	similar	(Figure	1D).	Among	pa-
tients	with	food	allergy,	a	nonspecialist	was	more	likely	to	prescribe	
antihistamines	 (37%)	and	corticosteroids	 (32%)	 than	an	adrenaline	
autoinjector	(27%).
Antihistamines	 and	 corticosteroids	 for	 drug-allergic	 patients	
were	prescribed	similarly	often	 in	and	outside	 the	allergy	centers;	
adrenaline	autoinjectors	were	surprisingly	provided	mainly	by	spe-
cialists	(17%	vs	4%;	Figure	1B	and	D).
Trigger	avoidance	counseling	and	emergency	management	train-
ing	(including	drug	training)	were	offered	to	approximately	40%	of	
patients	with	venom	allergy,	30%	of	patients	with	food	allergy,	and	
25%	(counseling)	and	11%	(training)	of	patients	with	drug	allergy	be-
fore	visiting	the	specialized	center.
These	data	reveal	that	the	standard	of	care	for	anaphylaxis	pa-
tients	 in	specialized	centers	 is	high.	However,	before	the	visit	 to	a	
center	less	than	half	of	the	patients	were	offered	adequate	prophy-
laxis	to	handle	the	next	reaction.
3.3 | Eighty‐four percent of the patients with an 
absolute indication for an adrenaline autoinjector 
according to EAACI guidelines were prescribed one
The	EAACI	guidelines	defined	six	groups	of	patients	with	an	abso-
lute	indication	for	an	adrenaline	autoinjector:	history	of	food,	latex,	
or	 aeroallergens	 anaphylaxis	 (a);	 exercise-induced	 anaphylaxis	 (b);	
idiopathic	 anaphylaxis	 (c);	 coexisting	 asthma	 and	 food	 allergy	 (d);	
venom	allergy	without	receiving	SIT	(e);	and	venom	allergy	and	mast	
cell	 disorder	 (f).	 In	 our	 dataset,	 4032	 cases	 fulfilled	 one	 of	 these	
criteria.	The	information	on	adrenaline	autoinjector	prescription	was	
provided	 in	3817	cases.	Of	 these,	84%	were	prescribed	an	adren-
aline	 autoinjector	 (before	or	 during	 a	 consultation	 in	 a	 specialized	
center;	Figure	2A).	Guideline	adherence	was	very	good	in	patients	
with	 venom	 allergy	 (91%),	 followed	 by	 food-induced	 anaphylaxis	
(85%;	Figure	2C).	Patients	with	latex	allergy,	idiopathic	anaphylaxis,	
and	anaphylaxis	caused	by	other	elicitors	were	less	often	prescribed	
an	autoinjector	(67%,	70%,	and	72%,	respectively;	Figure	2C).
The	group	of	patients	that	required	adrenaline	autoinjector	pre-
scription	before	visiting	a	specialized	center	was	larger	(n	=	6088)	be-
cause	in	the	majority	of	cases	venom	immunotherapy	was	initiated	
at	first	at	a	specialized	center	and	these	patients	were	not	protected	
by	 immunotherapy	 until	 then;	 thus,	 they	 must	 be	 prescribed	 an	
adrenaline	autoinjector.	Within	this	group,	the	information	on	adren-
aline	autoinjector	prescription	was	provided	in	4751	cases.	Despite	
the	EAACI	guidelines,	63%	of	the	patients	did	not	receive	an	auto-
injector	prescription	before	visiting	a	specialized	center	(Figure	2B).	
The	patients	with	venom	allergy	(47%)	were	most	likely	to	receive	an	
adrenaline	autoinjector	prescription,	followed	by	patients	with	food	
allergy	(27%)	and	idiopathic	anaphylaxis	(24%;	Figure	2D).
3.4 | Patients from countries without 
reimbursement were prescribed fewer adrenaline 
autoinjectors
Next,	we	analyzed	whether	the	reimbursement	status	has	an	impact	
on	the	frequency	of	adrenaline	autoinjector	prescription.	Among	the	
countries	 contributing	 to	 the	 registry,	 autoinjectors	 are	 not	 reim-
bursed	in	Poland,	Bulgaria,	and	Brazil.	Moreover,	in	Brazil	autoinjec-
tors	 are	 not	 available	 at	 local	 pharmacies	 and	have	 to	 be	ordered	
from	specialized	companies.	This	situation	was	reflected	in	our	data,	
as	patients	from	Brazil	received	notably	less	adrenaline	autoinjector	
prescriptions	 than	 patients	 from	other	 countries	 (38%	 (n	 =	 48)	 vs	
79%	 (n	 =	 163)	 in	 European	 countries	without	 reimbursement	 and	
85%	(n	=	3607)	in	European	countries	with	reimbursement;	data	not	
shown).
3.5 | Elicitor and severity of the reaction, 
age of the patient, mastocytosis as comorbidity, and 
reimbursement/availability of the autoinjector 
influence physician's decision to prescribe one
To	 compare	 factors	 influencing	 the	 physicians’	 decision	 regarding	
adrenaline	autoinjector	prescription,	a	multivariate	analysis	was	per-
formed	(Table	1).	Panel	A	presents	results	based	on	EAACI	guideline	
adherence	in	total;	panel	B	presents	the	analysis	of	the	adherence	
to	the	guidelines	among	emergency	and	primary	care	physicians.	In	
both	models,	the	reaction	severity	(Ring	&	Messmer,	grades	III	and	IV	
vs	grade	II)	and	venom	as	the	elicitor	were	associated	with	a	higher	
probability	to	receive	an	adrenaline	autoinjector	 (P	≤	 .001).	Higher	
age	(P	<	.001	in	both	models)	and	the	country	of	residence	with	no	
reimbursement	(P	=	.02	in	the	overall	model)	were	negatively	associ-
ated.	Mastocytosis	was	an	important	predictor	in	the	overall	model	
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(OR	=	3.03,	P	=	.036).	In	addition,	Brazilian	patients	had	a	remarkably	
lower	probability	to	receive	an	adrenaline	autoinjector	 (OR	=	0.11,	
P	<	.001).	Sex	and	cardiovascular	diseases	of	the	patient	had	no	influ-
ence	on	physicians’	decision.
3.6 | Prescription of more than one adrenaline 
autoinjector
Of	597	patients,	65%,	33%,	and	2%	were	prescribed	one,	two,	and	
more	than	two	autoinjectors,	respectively	(Figure	S2A).	In	the	multi-
variate	analysis	(Table	S2),	the	probability	to	receive	two	devices	was	
increased	in	patients	with	mastocytosis	(OR	=	5.74,	P	=	.026),	whereas	
it	was	decreased	in	patients	with	food	allergy	compared	with	those	
with	venom	allergy	(OR	=	0.31,	P	=	.011).	Pediatric	patients	were	more	
often	prescribed	two	or	more	autoinjectors	than	adult	patients	with	a	
clear	cutoff	during	the	transition	from	childhood	to	adulthood	(Table	
S2,	Figure	S2B).	The	dosage	of	adrenaline	(150	vs	300	µg)	was	usually	
selected	according	to	weight	(300	µg	for	>30	kg;	data	not	shown).
4  | DISCUSSION
Our	data	provide	basically	a	positive	outcome	regarding	the	range	of	
preventive	measures	offered	to	anaphylaxis	patients.	In	most	cases,	
adequate	measures	were	offered,	 and	EAACI	guideline	adherence	
regarding	autoinjector	prescription	 (84%)	was	satisfying.	However,	
this	perspective	is	strongly	influenced	by	the	structure	of	the	regis-
try;	the	cases	entered	into	the	database	were	recorded	by	allergists	
in	a	cooperating	center,	and	we	had	no	data	regarding	the	patients	
who	never	reach	these	healthcare	facilities	(which	may	be	depend-
ing	on	the	country/region	the	majority	of	the	patients).	The	second	
main	 source	 of	 bias	may	 be	 the	 definition	 of	 particular	measures,	
such	as	 “counseling	about	avoidance	of	 the	 trigger”	or	 “training	 in	
emergency	 management	 plan,	 including	 drug	 training”	 that	 can	
strongly	vary	with	 regard	 to	 their	extent,	as	no	minimal	standards	
for	those	measures	were	defined	in	the	questionnaire.
A	more	differentiated	image	of	secondary	prevention	measures	
appears	on	analyzing	the	data	regarding	prescription	and	counseling	
F I G U R E  2  Proportion	of	patients	who	were	prescribed	an	adrenaline	autoinjector	according	to	absolute	indications	of	EAACI	guidelines	
at	any	time	(before	or	during	the	visit	in	the	specialized	center)	(A	and	C;	n	=	3817)	or	before	visiting	the	specialized	allergy	center	(B	and	D;	
n	=	4751).	In	panels	C	and	D,	the	results	for	different	elicitors	are	shown:	unknown	(Panel	C:	n	=	380;	D:	n	=	291),	food	(Panel	C:	n	=	2637;	D:	
n	=	1894),	insects	(Panel	C:	n	=	703;	D:	n	=	2491),	latex	(Panel	C:	n	=	18;	D:	n	=	17),	and	others	(Panel	C:	n	=	77;	D:	n	=	58)	containing	mostly	
Anisakis	(Panel	C:	n	=	31;	D:	n	=	27),	aeroallergens	(Panel	C:	n	=	21,	D:	n	=	19),	and	exercise-induced	anaphylaxis	(	Panel	C:	n	=	11;	D	n	=	6).	
The	differences	in	absolute	numbers	between	panel	A	and	C	vs	panel	B	and	D	result	from	1)	the	exclusion	of	patients	presenting	within	or	
directly	after	the	anaphylactic	reaction	in	the	specialized	center	in	panel	B	and	D,	and	2)	number	of	patient	with	venom	allergy	undergoing	
SIT	and	therefore	not	having	an	absolute	indication	for	an	autoinjector	according	to	EAACI	guidelines
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patterns	outside	specialized	centers;	the	data	revealed	that	the	mini-
mal	protection	in	the	form	of	an	adrenaline	autoinjector	prescription	
was	offered	to	37%	of	the	patients,	who	had	an	absolute	indication	
for	 it.	This	 low	emphasis	on	secondary	prevention	measures	might	
be	related	to	the	fact	that	patients	may	not	always	be	advised	before	
the	proper	allergological	work-up,	and	that	the	primary	care	physi-
cian	referred	the	patient	to	a	specialized	allergy	center.	However,	the	
fact	that	70%	of	patients	who	had	an	anaphylaxis	to	food	with	se-
verity	grade	III/IV	left	the	emergency	department	and	went	through	
primary	care	without	a	prescription	for	an	autoinjector	is	alarming.	
Our	findings	are	in	 line	with	a	population-based	study	by	Kilger	et	
al16	who	analyzed	the	emergency	medication	prescribed	to	children	
after	anaphylaxis	in	Dresden	(Germany)	and	showed	that	only	26%	
of	 the	 children	 were	 prescribed	 an	 autoinjector.	 Another	 popula-
tion-based	 study	 conducted	 in	Canada	 reported	 that	 45%-55%	of	
patients	with	food	allergy	have	an	autoinjector.17
Interestingly,	 the	 elicitor	 of	 the	 reaction	 appears	 to	 be	 an	 im-
portant	factor,	influencing	physicians’	decision	regarding	emergency	
drug	 recommendation;	patients	with	 food	allergy	were	prescribed	
emergency	medication	less	frequent	than	those	with	venom	allergy.	
This	difference	was	substantial,	particularly	with	regard	to	autoin-
jector	prescription	outside	an	allergy	center	 (48%	vs	27%).	As	this	
effect	remained	significant	in	the	multivariate	analysis,	it	cannot	be	
explained	by	the	difference	in	the	patients’	age	or	reaction	severity.
Most	cases	 in	 the	 registry	are	 from	high	GDP	European	coun-
tries,	and	no	data	on	the	individual	socioeconomic	background	are	
collected.	Therefore,	the	Anaphylaxis	Registry	is	not	the	appropriate	
database	to	analyze	the	differences	regarding	this	 issue.	However,	
the	data	sample	from	Brazil	gives	a	hint,	how	unequally	the	access	to	
adequate	secondary	prevention	measures	is	distributed	worldwide.	
The	differences	according	to	gross	domestic	product	per	capita/re-
imbursement	of	 the	autoinjector	 (no	by	chance	 the	 two	European	
countries	from	the	registry	without	reimbursement	are	also	the	ones	
with	the	lowest	gross	domestic	income)	were	present	and	significant	
in	 the	multivariate	 analysis;	 however,	 the	 differences	were	 not	 as	
notable	 as	 expected.	This	 can	be	partially	 related	 to	 the	 fact	 that	
our	 collaborating	 centers	 in	 the	 countries	without	 reimbursement	
are	mainly	placed	in	big	cities;	therefore,	they	may	attract	a	selected,	
higher-income	population.	On	the	other	hand,	we	have	no	informa-
tion,	 if	 the	 prescriptions	 issued	by	 the	physicians	were	 later	 filled	
in	 the	pharmacy	and,	as	studies	 from	the	United	States	show,	not	
being	able	to	afford	medication	is	the	most	common	reason	for	not	
well-off	patients	to	not	fill	the	prescriptions.18,19
Individual	characteristics	of	the	patients	had	 little	 influence	on	
preventive	measures	 offered	 to	 them.	 Two	 groups	 received	 auto-
injector	 prescriptions	 less	 frequently:	 babies	 and	 elderly	 patients	
(data	not	shown).	This	can	be	explained	by	 the	 fact	 that	 there	are	
no	devices	with	an	accurate	dosage	for	babies,	and	elderly	patients	
are	prescribed	adrenaline	less	often	possibly	because	of	multiple	co-
morbidities,	even	though	cardiovascular	diseases	themselves	seem	
to	have	no	influence	on	physicians’	decision.	These	findings	should	
be	addressed	by	further	research	as	elderly	patients	are	particularly	
prone	to	severe	reactions.20,21
Children	were	significantly	more	often	prescribed	two	autoinjec-
tors,	which	is	striking	because	of	the	rough	cutoff	at	the	end	of	sec-
ond	decade	(Figure	S2B).	This	may	reflect	the	differences	in	behavior	
of	pediatric	allergist	and	other	specialties	or	be	caused	by	physician's	
emphasis	 on	 special	 needs	 of	 children.	 In	 this	 case,	 the	 European	
Medicines	Agency	(EMA)	recommendations	to	prescribe	additional	
adrenaline	autoinjector	 for	 the	use	 in	 the	 school	might	have	been	
crucial.
Overall,	our	data	highlight	the	importance	of	specialized	allergy	
centers	 and	 allergists	 in	 terms	 of	 providing	 adequate	 secondary	
prevention	 measures	 to	 individuals	 with	 anaphylaxis.	 Healthcare	
standards,	except	 for	 those	of	 specialized	 facilities,	were	 found	 to	
be	insufficient	as	in	most	cases	the	international	guidelines	were	not	
followed.	 This	 implicates	 the	 requirement	 of	 better	 education	 for	
emergency	doctors	and	primary	healthcare	providers	to	emphasize	
the	 importance	of	 the	 secondary	prevention	measures	 in	 anaphy-
laxis	patients.
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